OD-OS Achieves Revocation of Iridex MicroPulse™ Patent and Clears Path to Tissue-Friendly Treatment With Navilas® in Clinical Practice

TELTOW, Germany and IRVINE, California, July 16, 2018 /PRNewswire/ -- OD-OS, the global leader in the development and commercialization of navigated retinal laser systems, has achieved the revocation of the MicroPulse™ Patent (Patent no EP1856774) by IRIDEX Corporation in oral proceedings at the European Patent office held last Friday in Munich, Germany.

With its successful opposition, OD-OS has cleared the path to manufacture and market its Navilas® Laser System with microsecond pulsing technology. Navilas® features computer-assisted laser delivery and digital documentation, thus making subthreshold treatment of retinal diseases more predictable, and easier to reproduce in standard clinical practice.

The technology of using laser pulses down to 25 microseconds for retinal care has been introduced and marketed by Iridex as MicroPulse™ laser. MicroPulse™ is a trademark of Iridex Corporation.

Winfried Teiwes, Managing Director, OD-OS GmbH: “We fully respect the effort Iridex Cooperation has put into the clinical development how tissue-sparing, shorter laser pulses can be effective for retinal treatments. With Navilas®, we are providing a contact free, easy to use and transparent delivery technique of these laser pulses, which allows standardized treatment protocols. We will work with Navilas® users to make microsecond pulse treatment a non-contact, non-damaging but long-lasting treatment in clinical practice, and a viable addition to often chronical injections.”

Several studies have presented recent evidence on the effectiveness of navigated microsecond pulsing with Navilas®, e.g. for treating focal leakage in chronic central serous chorioretinopathy (www.od-os.com/publications).

Main benefits of tissue-friendly treatment with the Navilas® Laser System:

• Image-guided, pre-planned laser delivery allows for systematic application of confluent laser pattern without overheating through adjacent spot delivery, which avoids overlapping application of laser pulses.
• Digital documentation enables users to develop a simplified treatment parameter set that can be applied in standard clinical practice.
• Non-contact application of microsecond pulses with Navilas® makes this treatment very comfortable for patients and easy to apply for users.

About Navilas®: Navilas® laser systems enable physicians to digitally pre-plan the entire laser therapy on fundus images as well as on third-party diagnostic images, and to precisely execute this therapy plan with the help of computerized image guidance.

About OD-OS: OD-OS GmbH is a privately-held medical device company founded in 2008 with offices in Teltow, Germany, and Irvine, CA. www.od-os.com

For further information, please contact:
Stefanie Gehrke, Director Marketing | stefanie.gehrke@od-os.com, +49 (172) 3808 537
OD-OS GmbH | Warthestr. 21 | 14513 Teltow | Germany

View original content with multimedia:http://www.prnewswire.com/news-releases/od-os-achieves-revocation-of-iridex-micropulse-patent-and-clears-path-to-tissue-friendly-treatment-with-navilas-in-clinical-practice-300681630.html

SOURCE OD-OS GmbH